This clinical study looks at how well calderasib works with another medicine called pembrolizumab for people with non-small cell lung cancer (NSCLC). Researchers want to see if this combination helps people live longer without the cancer growing compared to pembrolizumab with chemotherapy. Calderasib is aimed at treating a specific mutation in the cancer cells.
The trial's ID number is NCT07190248. This is a Phase 3 trial, which means it is looking at how well the treatments work and their safety. It is regulated by the FDA, and about 675 participants are expected to take part.
Who can join
This study is open to adults aged 18 and older, both men and women. You can join if you have a specific type of advanced non-small cell lung cancer that cannot be treated with surgery. If you have HIV, it must be well controlled. Some people cannot join, such as those with other types of lung cancer, certain active diseases, or who have had specific treatments before. The trial team will check eligibility for each person.
Condition
Non-small Cell Lung Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive calderasib and pembrolizumab along with another medicine called berahyaluronidase alfa. The other group will receive pembrolizumab and berahyaluronidase alfa plus chemotherapy with either pemetrexed and carboplatin or cisplatin. Treatments will continue for up to 18 cycles, or around two years, depending on how well they work.
Where
This trial is enrolling at 9 locations. Recruiting sites are listed first.
Blue Ridge Cancer Care ( Site 0144)
Roanoke, Virginia
Recruiting
Central Alabama Research ( Site 0108)
Birmingham, Alabama
Recruiting
Indiana University Health Arnett Cancer Center ( Site 0116)
Lafayette, Indiana
Recruiting
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111)
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.